Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 8/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | FKBP5 | Q13451 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249847 | 0.90 | NPSR1 (0.39) | NPSR1F2PRSS1OPRM1STAT3 | |
| SCHEMBL8250731 | 0.86 | ELANE (0.36) | CTSK | |
| SCHEMBL12606095 | 0.85 | NPSR1 (0.40) | NPSR1F2PRSS1PLATBIRC2 | |
| SCHEMBL16329146 | 0.84 | BIRC2 (0.36) | NPSR1F2PRSS1PLATBIRC2 | |
| SCHEMBL12606094 | 0.84 | BIRC2 (0.36) | NPSR1F2PRSS1PLATBIRC2 | |
| SCHEMBL8248226 | 0.84 | DPP4 (0.38) | NPSR1F2PRSS1OPRM1F10 | |
| SCHEMBL12606105 | 0.84 | NPSR1 (0.39) | NPSR1F2PRSS1PLATBIRC2 | |
| SCHEMBL8247918 | 0.83 | DPP4 (0.38) | NPSR1F2PRSS1OPRM1STAT3 | |
| SCHEMBL8253477 | 0.83 | DPP4 (0.38) | NPSR1F2PRSS1OPRM1STAT3 | |
| SCHEMBL12606015 | 0.83 | NPSR1 (0.36) | NPSR1F2PRSS1PLATBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006130626-A2 | METHOD FOR MODULATING ACTIVITY OF HCV PROTEASE THROUGH USE OF A NOVEL HCV PROTEASE INHIBITOR TO REDUCE DURATION OF TREATMENT PERIOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |